object
aim
studi
assess
effect
commerci
aurintricarboxyl
acid
ata
cryptosporidium
parvum
method
anticryptosporidi
effect
ata
evalu
vitro
use
cell
cultur
doubl
fluorogen
stain
vivo
experiment
infect
neonat
mice
mice
oral
treat
consecut
day
start
day
infect
daili
ata
dose
mmolkg
paromomycin
mgkg
use
posit
control
result
vitro
model
ata
concentr
mmoll
complet
inhibit
sporozoit
within
min
respect
viabil
oocyst
expos
mmoll
assess
flow
cytometri
cell
cultur
reduc
respect
treatment
neonat
mice
daili
ata
dose
mmolkg
led
inhibit
infect
without
observ
neg
effect
anim
comparison
mean
reduct
infect
paromomycin
conclus
ata
exert
high
anticryptosporidi
activ
consid
studi
cryptosporidiosi
respons
sever
intestin
disord
wide
rang
host
infect
typic
found
aid
patient
immunocompromis
person
cryptosporidium
speci
also
common
danger
waterborn
pathogen
cryptosporidium
parvum
one
frequent
caus
enter
diarrhoea
postnat
calv
lamb
goat
kid
agricultur
import
anim
econom
hygien
zoohygien
impact
cryptosporidiosi
signific
control
infect
human
veterinari
practic
complic
lack
effect
therapi
although
immunotherapi
mainli
administr
hyperimmun
colostrum
may
improv
clinic
statu
patient
chemotherapi
main
therapeut
approach
howev
none
known
anticryptosporidi
drug
paromomycin
azithromycin
nitazoxanid
use
mostli
human
halofuginonelact
approv
anticryptosporidi
therapi
calv
absolut
effect
better
anticryptosporidi
drug
minim
residu
toxic
still
need
human
veterinari
clinic
practic
one
drug
potenti
anticryptosporidi
use
aurintricarboxyl
acid
ata
shown
ata
minim
toxic
biolog
highli
activ
exampl
ata
potent
inhibitor
endonucleas
activ
proteinnucl
acid
interact
ata
also
inhibit
angiogenesi
von
willebrand
factor
bind
platelet
thu
prevent
blood
coagul
antimicrobi
properti
ata
also
describ
compound
suppress
yersinia
pesti
pathogen
interestingli
found
ata
also
strongli
inhibit
replic
coronaviru
caus
sever
acut
respiratori
syndrom
sar
contrast
data
antiprotozo
activ
compound
avail
aim
studi
assess
efficaci
ata
c
parvum
use
vitro
vivo
laboratori
model
commerci
avail
ata
sigmaaldrich
freshli
dissolv
dimethylsulfoxid
prepar
stock
solut
work
solut
mmoll
subsequ
prepar
dilut
stock
solut
dmem
pb
cell
cultiv
flow
cytometri
respect
fresh
oocyst
c
parvum
obtain
human
aid
patient
viabil
assess
use
stain
dapi
propidium
iodid
use
excyst
assay
intact
oocyst
free
sporozoit
examin
separ
vitro
anticryptosporidi
activ
ata
evalu
use
flow
cytometri
cell
cultur
model
describ
detail
previous
concis
flow
cytometri
assay
oocyst
sporozoit
expos
three
differ
concentr
drug
min
parasit
stain
fluorescein
diacet
propidium
iodid
analys
flow
cytometri
analysi
demonstr
presenc
four
popul
organ
greenfluoresc
organ
viabl
cell
ii
redfluoresc
organ
nonviabl
organ
iii
organ
show
red
green
fluoresc
injur
die
cell
iv
particl
show
fluoresc
cellular
debri
cystic
form
poorli
permeabl
fluorescein
diacet
vitro
cell
cultur
test
fresh
confluent
monolay
cell
experiment
infect
intact
oocyst
sporozoit
also
previous
expos
three
test
concentr
drug
min
infect
cell
cultiv
parasit
h
standard
condit
intens
infect
assess
random
field
use
nomarski
interfer
contrast
optic
meront
gamont
enumer
avoid
count
nonviabl
adher
sporozoit
merozoit
threedayold
spf
babi
mice
velaz
czech
republ
randomli
assign
group
nine
avoid
reject
pup
random
babi
mice
wet
urin
adopt
mother
place
respect
nest
experi
initi
day
later
ensur
pup
healthi
babi
mice
maintain
togeth
adopt
mother
steril
microisol
equip
filter
top
tecniplast
itali
cage
open
biosafeti
cabinet
steril
water
standard
food
pellet
administ
ad
libitum
mous
litter
assign
one
five
group
follow
group
infect
treat
ata
daili
dose
mmolkg
group
b
infect
receiv
ata
daili
dose
mmolkg
group
c
uninfect
receiv
ata
daili
dose
mmolkg
group
infect
treat
paromomycin
mgkgday
posit
control
group
e
infect
receiv
pb
control
oocyst
c
parvum
isol
vuzvn
propag
neonat
holstein
calf
week
experi
oocyst
purifi
secondari
sucros
gradient
surfacesteril
sodium
hypochlorit
wash
three
time
steril
pb
oocyst
store
steril
pb
use
vivo
model
modifi
follow
mice
oral
infect
oocyst
treatment
initi
time
daili
dose
ata
divid
two
equal
portion
oral
administ
h
interv
paromomycin
duchefa
biochemi
netherland
dissolv
deioniz
water
oral
administ
h
interv
ata
use
vitro
test
freshli
prepar
use
complet
dissoci
aqueou
naoh
atanaoh
molar
ratio
filtersteril
steril
mm
pore
size
syring
filter
treatment
continu
day
period
mice
weigh
daili
adjust
drug
dosag
monitor
growth
mice
euthan
cervic
disloc
h
complet
treatment
intestin
tract
duodenum
rectum
extract
weigh
homogen
resuspend
ml
cold
pb
homogen
vigor
shaken
volum
cold
petroleum
ether
centrifug
min
g
extract
fat
mucu
petroleum
ether
discard
pellet
resuspend
pb
suspens
treat
sodium
hypochlorit
wash
three
time
pb
volum
adjust
initi
weight
extract
intestin
oocyst
enumer
haemocytomet
intens
infect
express
number
oocyst
extract
mg
intestin
tissu
correctli
diagnos
infect
aliquot
intestin
extract
concentr
four
time
centrifug
also
examin
acidfast
stain
techniqu
onethird
pb
volum
concentr
sampl
replac
bovin
blood
plasma
sampl
smear
onto
slide
slide
dri
fix
stain
carbolfuchsin
describ
previous
vivo
experi
repeat
second
time
use
protocol
result
statist
evalu
nonparametr
anova
statist
packag
qc
expert
version
trilobyt
czech
republ
flow
cytometri
demonstr
percentag
viabl
sporozoit
decreas
undetect
level
min
exposur
mmoll
ata
respect
figur
ata
mmoll
reduc
oocyst
viabil
figur
similarli
cell
cultur
complet
inhibit
parasit
growth
observ
min
exposur
sporozoit
mmoll
ata
respect
figur
oocyst
seri
ata
exposur
result
reduct
mmoll
figur
flow
cytometri
cell
cultur
assay
show
high
activ
ata
free
sporozoit
surprisingli
also
oocyst
data
obtain
repeat
vitro
test
produc
analog
result
data
shown
mice
dosedepend
inhibit
infect
ata
observ
figur
wherea
mean
inhibit
anim
treat
mmolkg
p
experi
ii
respect
dose
mmol
kg
reduc
infect
p
addit
anim
treat
higher
drug
dose
particularli
experi
ii
found
c
parvumneg
end
treatment
treatment
paromomycin
mgkg
led
mean
inhibit
infect
p
figur
nevertheless
paromomycin
exert
slight
toxic
caus
moder
depress
growth
averag
daili
weight
gain
mice
group
age
day
g
contrast
averag
daili
gain
group
c
e
period
g
indic
ata
observ
neg
effect
anim
avail
data
toxic
ata
unclear
commerci
avail
ata
prepar
contain
usual
impur
possibl
toxic
ata
differ
sourc
may
vari
moreov
mani
biolog
studi
compound
distinguish
ammonium
salt
ata
known
also
aluminon
ata
toxicolog
studi
ata
therefor
necessari
result
vivo
experi
nevertheless
consist
result
balzarini
et
al
found
ld
ata
mice
high
gkg
mechan
ata
inhibit
parasit
compound
therapeut
target
also
remain
unknown
inde
commerci
ata
use
biolog
studi
includ
present
chemic
compound
whose
chemic
structur
still
discuss
ata
origin
thought
triphenylmethan
dye
dye
structur
still
incorrectli
use
much
atarel
literatur
commerci
avail
ata
actual
heterogen
mixtur
polym
phenol
formaldehyd
type
addit
known
ata
readili
polymer
biolog
activ
vari
molecular
weight
studi
effect
ata
fraction
nuclear
swell
vitro
rna
dna
synthesi
even
found
signific
biolog
activ
attribut
formaurindicarboxyl
acid
impur
found
commerci
prepar
ata
wherea
pure
ata
found
almost
inact
complet
understand
relationship
chemic
structur
biolog
properti
ata
essenti
ata
consid
clinic
use
includ
antiprotozo
drug
data
indic
commerci
ata
prepar
strong
anticryptosporidi
activ
treatment
well
toler
mice
light
limit
therapeut
option
treat
cryptosporidiosi
evalu
ata
clearli
justifi
flow
cytometr
analysi
oocyst
expos
aurintricarboxyl
acid
ata
studi
support
ministri
agricultur
czech
republ
project
